S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

$5.35
-0.49 (-8.39%)
(As of 03/28/2024 ET)
Today's Range
$5.15
$5.90
50-Day Range
$5.35
$7.75
52-Week Range
$2.09
$8.17
Volume
318,061 shs
Average Volume
187,515 shs
Market Capitalization
$112.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

Syros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
130.5% Upside
$12.33 Price Target
Short Interest
Bearish
9.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.66mentions of Syros Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.75) to ($2.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.21 out of 5 stars

Medical Sector

184th out of 939 stocks

Pharmaceutical Preparations Industry

77th out of 441 stocks

SYRS stock logo

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock Price History

SYRS Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Syros Pharmaceuticals earnings preview: what Wall Street is expecting
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
SYRS Apr 2024 10.000 call
SYRS Jul 2024 2.500 call
Syros Pharmaceuticals, Inc. (SYRS)
SYRS Mar 2024 7.500 put
Syros Pharmaceuticals Inc.
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/05/2021
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.33
High Stock Price Target
$15.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+130.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-94,650,000.00
Pretax Margin
-1,193.45%

Debt

Sales & Book Value

Annual Sales
$14.88 million
Book Value
$6.32 per share

Miscellaneous

Free Float
18,865,000
Market Cap
$112.72 million
Optionable
Optionable
Beta
1.79
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Richard A. Young Ph.D. (Age 70)
    Scientific Founder, Member of Scientific Advisory Board & Director
    Comp: $108.37k
  • Dr. David A. Roth M.D. (Age 61)
    Chief Medical Officer
    Comp: $679.52k
  • Mr. Conley Chee (Age 54)
    CEO, President & Director
  • Dr. James E. Bradner M.D. (Age 52)
    Founder
  • Dr. Nathanael S. Gray Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Jason Haas (Age 56)
    Chief Financial Officer
    Comp: $457.22k
  • Ms. Karen Hunady M.S.
    Director of Corporate Communications & Investor Relations
  • Mr. Gerald E. Quirk Esq. (Age 56)
    J.D., Chief Legal Officer & Head of Business Development
    Comp: $127.07k
  • Ms. Lisa Roberts
    Vice President of Human Resources
  • Ms. Kristin Stephens (Age 51)
    Chief Development Officer

SYRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price target for 2024?

2 brokerages have issued 1-year target prices for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $7.00 to $15.00. On average, they anticipate the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 130.5% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2024?

Syros Pharmaceuticals' stock was trading at $7.79 at the start of the year. Since then, SYRS shares have decreased by 31.3% and is now trading at $5.35.
View the best growth stocks for 2024 here
.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,740,000 shares, an increase of 31.8% from the February 29th total of 1,320,000 shares. Based on an average daily volume of 212,500 shares, the days-to-cover ratio is currently 8.2 days. Currently, 9.6% of the shares of the stock are sold short.
View Syros Pharmaceuticals' Short Interest
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Friday, November, 5th. The company reported ($4.10) earnings per share for the quarter, topping the consensus estimate of ($4.40) by $0.30. The firm had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.10 million. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative trailing twelve-month return on equity of 184.10%. During the same quarter in the previous year, the company posted ($4.30) earnings per share.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split before market open on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (13.05%), Avidity Partners Management LP (7.94%), Blue Owl Capital Holdings LP (7.09%), Point72 Asset Management L.P. (6.99%), Flagship Pioneering Inc. (6.14%) and Vanguard Group Inc. (3.63%). Insiders that own company stock include David Roth, Eric R Olson, Srinivas Akkaraju and Timothy Tyson.
View institutional ownership trends
.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYRS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners